Bristol Myers Squibb Appoints EVP and Announces Major US Investment
Bristol Myers Squibb has announced two major developments: the appointment of Cari Gallman as Executive Vice President, General Counsel and Chief Policy Officer, and a commitment to invest $40 billion in the United States over the next five years.
Gallman, who succeeds the retiring Sandra Leung, brings a decade of leadership at Bristol Myers Squibb and extensive experience in pharmaceutical law, compliance, and policy. She will oversee the company’s legal, policy, and government affairs functions, aiming to uphold ethical standards and support innovation for patients facing serious diseases.
“Cari brings a unique combination of legal, policy and communications expertise, coupled with an impressive ability to inspire teams, uphold ethical business practices and champion patient voices,” said Christopher Boerner, Board Chair and Chief Executive Officer, Bristol Myers Squibb. “I am confident that under Cari’s leadership, our legal and policy teams are well-positioned to advance Bristol Myers Squibb’s efforts to drive and deliver innovation to patients facing serious diseases.”
“It is an honor to have the opportunity to lead the incredible teams that govern and counsel Bristol Myers Squibb in advancing its mission to deliver transformational medicines to more patients,” said Gallman. “I am committed to continuing to build on the company’s culture of integrity and shape a dynamic policy environment that protects innovation and patients.”
Simultaneously, Bristol Myers Squibb’s $40 billion investment will be directed toward expanding US research and development, technology, and manufacturing capabilities, as outlined in an editorial for Stat by Boerner.
In his editorial, Boerner praised the administration’s efforts to bolster domestic manufacturing but warned that “tariffs on pharmaceuticals could lead to shortages or higher costs to patients.”
“Policies that undermine regulatory certainty, eliminate funding for basic medical research, or weaken intellectual property make it incrementally harder, if not impossible, to discover the next breakthroughs,” Boerner wrote.
